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low up periods (p=0.04), suggesting that the pre -
sence of antiphospholipid antibodies (aPL) was not
a transient phenomenon. Although aPL in le prosy
were frequent and b2GPI-dependent as those found
in APS, IgM was the predominant isotype, and there
was no association with thrombosis or other APS
manifestations. 
Keywords: Leprosy; Anti-b2-glycoprotein I antibo -
dies; Antiphospholipid antibodies; Anticardiolipin
antibodies; Antiphospholipid syndrome.
Introduction
Antiphospholipid antibodies (aPL) are a heteroge-
neous group of autoantibodies, which have been
reported in many autoimmune diseases, mainly in
systemic lupus erythematosus (SLE) and primary
antiphospholipid syndrome (APS), in association
with vascular thrombosis, pregnancy morbidity,
and a number of other less commonly found ma -
nifestations1. aPL have also been reported in the
context of several infections such as leprosy, tu-
berculosis, malaria, syphilis, hepatitis C virus
(HCV), human immunodeficiency virus (HIV), le -
ptospirosis, and B19 parvovirus infections2-5. Inter-
estingly, the presence of aPL in infectious di seases
is not usually associated with the clinical compli-
cations attributed to APS6, and they are often tran-
sient and may disappear after treatment7.
Anticardiolipin (aCL) antibodies constitute the
main group of aPL studied in primary and secon -
dary APS and other autoimmune and infectious
diseases. In the last two decades, several studies
have indicated that b2-glycoprotein I, a phospho-
lipid binding protein, besides its role as cofactor
for aCL antibodies detection8-10, may be itself an
antigen, eliciting pathogenic anti-b2-glycoprotein I
antibodies in APS11. 
Although the aCL antibodies detected in infec-
tious disorders were initially reported to be main-
Abstract
Objectives: To determine the prevalence of 
anticardiolipin (aCL) and anti-b2-glycoprotein I
(anti-b2GPI) antibodies in leprosy patients, during
and after specific multidrug therapy (MDT), and to
evaluate a possible association between these an-
tibodies and some clinical characteristics of le -
prosy, including clinical forms, reactional episodes
and treatment.
Methods: The study included 158 leprosy patients,
129 gender-and-age matched healthy individuals,
and 38 women with primary antiphospholipid syn-
drome (APS). Clinical and demographic characte -
ristic of leprosy patients were collected, and serum
samples, obtained from all participants, were kept
frozen at - 20°C. Antibodies were measured either
by an in house-developed ELISA (aCL) or by a com-
mercial ELISA (anti-b2GPI).
Results and Conclusions: Increased levels of aCL
and anti-b2GPI antibodies were found in leprosy
patients and in the APS group, however, in contrast
to APS, the predominant isotype in leprosy was
IgM. The frequency of aCL and anti-b2GPI anti-
bodies was significantly higher in leprosy patients
than in healthy individuals (15.8% vs. 3.1%; p<0.01;
46.2% vs. 9.4%, p<0.01), respectively. The leproma-
tous form predominated among aCL positive lep-
rosy patients (p<0.01). There was no difference in
aCL and anti-b2GPI positivity between leprosy pa-
tients taking MDT and those completed MDT as
cured. Furthermore the duration of discharged pe-
riod (period between discharge from MDT and 
the realization of the study) had no effect on 
anti-b2GPI positivity, and a slight increase in aCL
positivity was observed in patients with longer fol-
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ly b2GPI-independent, b2GPI-dependent aCL, and
antibodies against the proteins b2GPI and pro-
thrombin have also been reported in some infec-
tions12,13.
Leprosy is an infectious disease caused by My-
cobacterium lepraeaffecting primarily the periphe -
ral nervous system, and secondarily involving skin
and other tissues. The clinical spectrum is chara -
cterized by two stable poles forms of disease. At one
pole, tuberculoid leprosy, the host is able to keep
the disease under control due to an efficient T-cell-
-mediated immune response; while at opposite
pole, lepromatous leprosy, cell-mediated immu-
nity is inefficient leading to excessive bacillary mul-
tiplication and dissemination. Between the two
stable poles are unstable forms of leprosy, named
borderline that may combine characteristics of the
polar forms. A broad spectrum of clinical lesions
and a high frequency of autoantibodies, especial-
ly aCL antibodies are seen in leprosy14-16. Despite
the disease chronicity and the aCL persistence16,
aPL-related thromboembolic complications have
rarely been reported in leprosy17,18.
Although aCL have been reported in 20-98% of
leprosy patients with different clinical forms, it
seems to be more prevalent in the lepromatous
form3,4,15,16,19-24. The prevalence of anti-b2-glycopro-
tein I antibodies (anti-b2GPI) is highly variable,
ranging from 2.9 to 89%3,16,21,23,24.
The objectives of this study were to determine
the prevalence of aCL and anti-b2GPI antibodies in
a large number of Amazon leprosy patients taking
multidrug therapy (MDT) and in completed MDT
as cured, and to evaluate a possible association be-
tween these antibodies and clinical forms of di -
sease, and reactional episodes.
Patients and Methods
The study group included 158 leprosy patients (113
males and 45 females, mean age of 39.9±15.2 years)
followed up at the Tropical Dermatology and Vene-
real Clinic of Alfredo da Matta Foundation (Ma-
naus, Amazon, Brazil) from July 2004 to October
2006. Leprosy diagnosis was established according
to Ridley and Jopling classification criteria25. To de-
termine the presence of antiphospholipid anti-
bodies, 20 mL of peripheral venous blood were col-
lected from all participants. The leprosy patients
present with the following clinical and therapeu-
tic characteristics: Fifty-six cases had lepromatous,
35 borderline lepromatous, 25 borderline, 32 tu-
berculoid borderline, 6 tuberculoid, and 4 inde-
terminate form. Reactional episodes as erythema
nodosum lepromatosum (ENL), reversal reaction
(RR) and neuritis were present in 58/158 (36.7%)
of the patients, during the study. The criterion for
a diagnosis of ENL was the presence of tender skin
nodules. This could be accompanied by fever and
other systemic symptoms such as joint pain, bone
tenderness, neuritis, edema, malaise, anorexia,
and/or lymphadenopathy; for the reversal reac-
tion, acute inflammation, as pain, erithema, infil-
tration and edema of pre existing lesions some-
times accompanied of new lesions and neuritis.
Sixty four patients were taking MDT and 94 had al-
ready completed MDT. In those patients who com-
pleted MDT( period cured), the period between
discharge and the realization of the study ranged
from 1 to 115 months ( median of 31 months). All
were submitted to complete physical exam and a
questionnaire and none of them had any event
suggestive of APS (vascular thrombosis, pregnan-
cy morbidity or thrombocytopenia) or any con-
comitant rheumatic disease.
The control group was composed by 129 healthy
individuals, gender-and-age matched to the le -
prosy group (mean age of 40.9±14.1 years), living
in the same geographic region. The APS group was
constituted by 38 women with primary APS (mean
age of 40.2±13.8 years)26 , who were recruited from
a outpatient clinic of rheumatology, Universidade
Federal de São Paulo (UNIFESP), Brazil, meeting
the Sapporo criteria27. The most frequent manifes-
tations of these patients were pregnancy morbidi -
ty (44.7%), lower limb venous thrombosis (39.4%)
and stroke (28.9%). Many of them had more than
one manifestation. The age distribution of the APS
group did not differ from the leprosy and control
groups (p=0.649).
Blood samples were collected from all partici-
pants and kept at -20°C, until analyzed at the
Rheumatology Division of Universidade Federal
de São Paulo. The study was approved by both Ins -
titutional Review Boards, and all participants
signed the informed consent form. 
Anticardiolipin antibodies (aCL)
IgG and IgM aCL antibodies were tested in all
serum samples with an in house-developed ELISA.
Normal ranges for aCL antibodies in Brazilian po -
órgão of ic ial da soc iedade portuguesa de reumatologia - acta reumatol port. 2011;36:30-37
32
high prevalence of antibodies to b2gpi in leprosy
pulation were previously determined in a sample
of 200 healthy blood donors and the 95th per-
centile cutoff points, established with the use of in-
ternational APL calibrators (LAP-GM-200 calibra-
tors, Louisvulle APL Diagnostics, Inc, GA, USA)
were 20 GPL and 10 MPL, respectively. One GPL or
MPL unit is defined as the cardiolipin binding ac-
tivity of 1g/mL of an affinity purified IgG or IgM
aCL preparation from a standard serum.
Anti-b2-glycoprotein I antibodies
Serum IgG and IgM anti-b2GPI antibodies were
tested by a commercial ELISA (The Binding Site,
Birmingham, UK) according to the manufacturer’s
instructions. The cutoff values according to the kit
were 10 U/mL for IgM and 20 U/mL for IgG. Due
to our limitations, only 106 control sera were in-
cluded in this test.
Statistical analysis
Statistical analysis was performed with the SPSS
15.0.1 software (Chicago, USA). Kruskal-Wallis test
was used for age distribution comparison between
groups. Chi-square test was used to compare gen-
der distribution, and aCL and anti-b2GPI antibody
frequencies between groups. Binomial test was
used to compare the proportion of clinical forms
among aCL and anti-b2GPI antibodies positive le -
prosy patients. Student’s t-test was used to com-
pare duration of completed MDT (cured period)
and aPL positivity between groups. P values < 0.05
were considered statistically significant.
Results 
In the APS group aCL antibodies were positive in
34/38 (89.5%) patients, and GPL or MPL titers >40
U/mL were found in 26/34 (76.5%) of the positive
sera. In the leprosy group, aCL antibodies were
posi tive in 25/158 (15.8%) patients, and GPL or
MPL ti ters >40 U/mL were found in 20/25 (80%) of
the positive sera. There was no difference in aCL
positivity between leprosy patients in completed
MDT and those taking MDT (p=0.41). In the con-
trol group, aCL antibodies were found in only 4/129
(3.1%) individuals, none of them with GPL or MPL
titers higher than 40 U/mL. Anticardiolipin anti-
bodies were more frequent in leprosy patients than
in healthy controls (p <0.01), but less frequent than
in APS (p <0.01). Mean aCL titers in leprosy were
57 GPL U/mL and 56 MPL U/mL. 
Among the 25 aCL positive leprosy sera, IgM iso-
type was more frequent than IgG (88% vs 16%;
p<0.01). In contrast, in the APS group, IgG isotype
was more frequent than IgM (91.2% vs 44.1%, res -
pectively; p<0.01). All the four positive healthy con-
trols had IgM aCL antibodies (Table I).
The clinical forms of disease were not equally
distributed between aCL positive and negative le -
pro sy patients (p<0.01,) as shown on Table 2.
Among the aCL positive leprosy patients, the lepro -
ma tous form was found in a higher percentage
(72%) than the other forms (p<0.01), while among
aCL negative patients there was no predominant
form. There was no association between the pres-
ence of reactional episodes and aCL antibodies
(p=0.41). Ho wever, among the 58 leprosy patients
with reactional episodes, the distribution of reac-
tion type was different between aCL positive and
negative patients (p=0.03). ENL was the most
prevalent reaction type in both aCL positive and
aCL negative patients with reactional episodes,
however, all the aCL positive patients presented
ENL type (100%) while in aCL negative, ENL was
found in only 57.4% (p=0.02).
Anti-b2GPI antibodies were found in 9/38
(23.7%) patients of the APS group, and titers >40
Table I. Frequency of aCL and anti-β2GPI antibodies according to isotype distribution in leprosy patients,
healthy controls, and APS group
Leprosy patients Healthy controls Primary APS patients
(n=158) (n=129) (n=106) (n=38)
Isotype aCL anti-β2GPI aCL anti-β2GPI aCL anti-β2GPI
IgG alone 3 1 0 1 18 3
IgM alone 21 64 4 9 3 2
IgG + IgM 1 8 0 0 13 4
Total 25 (15.8%) 73 (46.2%) 4 (3.1%) 10 (9.4%) 34 (89.5%) 9 (23.6%)
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U/mL were found in 66.7% of them. In the leprosy
group, anti-b2-GP1 antibodies were found in 73/158
(46.2%) patients, and titers >40 U/mL were found
in 26 (35.6%) of them. There was no difference in
anti-b2GPI positivity between leprosy patients who
completed MDT and those taking MDT (p=0.07). In
the control group, anti-b2-GPI antibodies were
found in only 10/106 (9.4%) individuals, and none
of them had titers >40 U/mL. Anti-b2-GPI antibo -
dies were more frequent in leprosy patients than in
healthy controls (p<0.01) or APS (p=0.01). The
mean titers of anti-b2-GPI in leprosy patients were
112 U/mL for IgG and 94 U/mL for IgM antibodies.
Among the 73 anti-b2GPI positive leprosy sera,
IgM isotype was more frequent than IgG (97.3% vs.
12.3%, p<0.01). In the APS group, both isotypes
were equally frequent. Among the anti-b2GPI posi -
tive healthy controls, IgM isotype was also more
frequent than IgG (90% vs. 10%, respectively; 
p <0.01) (Table I).
The distribution of the clinical forms of disease
according the Ridley Jopling classification was simi -
lar in anti-b2GPI positive and negative leprosy pa-
tients (p=0.09), Table III. Anti-b2GPI positivity was
also similar in patients with and without reactio nal
episodes (51.7% vs. 43%, respectively, p=0.29),
There was no difference in the proportions of the
reaction types between anti-b2GPI positive and
negative patients (p=0.18).
Among the 158 leprosy patients, 77 (48.7%) were
positive for at least one aPL antibody (Figure 1).
Interestingly, as depicted in Table II, among the
Table II. Distribution of anticardiolipin antibody in leprosy patients accordingly to Ridley & Jopling 
classification
Classification
I TT BT BB BL LL TOTAL
aCL n % n % n % n % n % n % n %
Negative 4 3,0 6 4,5 31 23,3 22 16,5 32 24,1 38 28,6 133 100
Positive 0 0 0 0 1 4 3 12 3 12 18 72 25 100
TOTAL 4 2,5 6 3,8 32 20,3 25 15,8 35 22,2 56 35,4 158 100
aCL=anticardiolipin antibodies; BB=borderline; BV=borderline lepromatous; BT=borderline tubercuoid; I=indeterminated; TT=tuberculoid;
VV= lepromatous
Table III. Distribution of anti-b2GPΙ in leprosy patients accordingly to Ridley & Jopling classification
Classification
anti- I TT BT BB BL LL TOTAL
b2GPΙ n % n % n % n % n % n % n %
Negative 3 3,5 5 5,9 21 24,7 14 16,5 20 23,5 22 25,9 85 100
Positive 1 1,4 1 1,4 11 15,1 11 15,1 15 20,5 34 46,6 73 100
TOTAL 4 2,5 6 3,8 32 20,3 25 15,8 35 22,2 56 34,4 158 100
BB=borderline; BL=borderline lepromatous; BT=borderline tubercuoóid; I=indeterminated; TT=tuberculoid
Table IV. Prevalence of aCL and anti-ß2GPI antibodies among leprosy patients
aCL
Positive Negative TOTAL
anti-b2GPI
Positive 21 52 73
Negative 4 81 85
TOTAL 25 133 158
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25 aCL positive leprosy patients, 21 (95%) were also
positive for anti-b2GP1 antibodies (p<0.01).
Among the leprosy population under study, 94
patients had completed MDT in the period of sera
collection to test the antibodies aFL. This period
ranged from 1 to 115 months (median 31.3
months) and had no influence in anti-b2GPI posi -
tivity (p=0.20). A slight increase in aCL positivity
was observed in patients with longer time com-
pleted MDT (p=0.04).
Discussion
Antiphospholipid antibodies have been widely
studied in autoimmune diseases, and their asso -
cia tion with thrombotic events as well as preg-
nancy morbidity is well known. However, aPL re-
lated to some viral or bacterial infections are not
usually associated with the clinical manifestations
attributed to APS. This lack of pathogenicity was
first attributed to b2GPI independency, either as a
cofactor or as an autoantigen7-10.
Nevertheless, the distinction between autoim-
mune (APS associated), and infectious (b2GPI in-
dependent) aPL has been recently challenged, with
some studies reporting the occurrence of anti-
bodies to b2GPI in patients with viral or bacterial
infections3,23,28. 
In infectious diseases, aPL could be induced by
disturbances of cellular and humoral immune re -
gu lation, during the immune response. Alterna-
tively, this induction could be attributed to the ex-
posure of phospholipid antigens by tissue damage
in the course of infection. One current hypothesis
is that infections may be a «trigger» for the gene -
ration of pathogenic aPL in genetically predisposed
individuals4,29,30. In this case, bacterial or viral pepti -
des with homology to the b2GPI molecule would be
presented to T lymphocytes, which will stimulate
B lymphocytes to produce antibodies against the
cross-reacting heterologous sequence30.
Anticardiolipin and anti-b2GPI antibodies 
have been reported in leprosy patients, mainly 
in associa tion with lepromatous leprosy, and 
usually without APS-related clinical manifesta-
tions3,4,15,16,19-24.
In our study, the positivity of cofactor-depen-
dent aCL antibodies was lower than that reported
in other studies, although there is a large variabi -
lity in the literature3,4,16,20-24. This variability could
be attributed to methodological differences in-
cluding the cutoff value established for different
populations, variation in the reagents used 
in home-based assays, calibration aspects, and 
other factors31.
Our study selected a large cohort of leprosy pa-
tients representing the spectrum and clinical fea-
tures of the disease. The frequency of aCL anti-
bodies in our leprosy patients was higher in the
lepromatous form, in agreement with several au-
thors3,15,16,20,22,23, and the presence of aCL antibo dies,
even in high titers, was not associated with reac-
tional episodes. However, we observed that all pa-
tients with a reactional episode who were positive
for aCL presented erythema nodosum leprosy.
Seve ral studies addressed the isotype prevalence of
aPL in the sera from leprosy patients with varied
results. We observed a predominance of the IgM
isotype in aCL antibodies, corroborating the data
of some authors3, however, other studies found a
higher prevalence of the IgG isotype15,16,20, and one
study, in black South African patients, found a
higher prevalence of the IgA isotype4.
Antibodies with specificity towards b2GPI have
been suggested to be a better marker of APS than
aCL alone 32,34 and in 3-10% of APS patients, anti-
-b2GPI antibodies may be the only positive test35-37.
According to these evidences, recently, the pre -
sence of anti-b2GPI antibodies regardless of iso-
type was included as part of the modified Sapporo
classification criteria for APS27.
According to the literature, anti-b2GPI antibo -
dies are less frequently found in infectious diseases
than in APS12,13,32,34. Furthermore, most APS studies
have shown a relationship between IgG isotype
anti-b2GPI antibodies and venous thrombosis and
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lack of association with the IgM isotype12,32,34,38,39.
However, associations between IgM anti-b2GPI an-
tibodies and arterial thrombosis, fetal loss and
thrombocytopenia have also been reported in
APS39-43.
In the literature, the prevalence of anti-b2GPI
antibodies in leprosy ranges from 2.9% up to
89%4,21. We found anti-b2GPI antibodies in 46.2% of
leprosy patients, some of which displaying high
titers. In our leprosy population, IgM was the most
frequent isotype of anti-b2GPI antibodies, in agree-
ment with other studies3,4. However, another study,
including 177 leprosy patients, showed no favorite
isotype23.
In our study, 20.5% of the anti-b2GPI positive
leprosy patients had antibody titers higher than
100 U/mL. According to the literature, high titers
of anti-b2GPI antibodies are associated with risk of
thrombosis, but the definition of the boundaries
for medium and high titers is a difficult task27.
We found a higher prevalence of anti-b2GPI
(46.2%) than aCL (15.8%) antibodies in leprosy,
corroborating the results of Loizou et al (2003)4.
However, there are other studies reporting a hi gher
prevalence of aCL than of anti-b2GPI antibodies in
leprosy16,21.
Anticardiolipin and anti-b2GPI antibodies were
simultaneously found in 13.3% of our leprosy pa-
tients, and in 70% of those, antibody titers for both
specificities were higher than 40 U/mL. However,
in agreement with the literature, we found no as-
sociation between the presence of aCL and/or anti-
-b2GPI antibodies and thrombotic events3,4,23,24.
In APS, thrombotic events are usually associa -
ted with the IgG isotype of aCL and anti-b2GPI an-
tibodies. In our study, IgM was the most prevalent
isotype in leprosy whereas IgG was more frequent
in primary APS. It has been suggested that IgG iso-
type may be an important factor in determining
clinical complications of aCL.44 There is also an in-
teresting paper suggesting that IgG anti-b2GPI an-
tibodies specifically directed against a positively
charged epitope on the first domain of b2GPI cor-
relate with thrombosis45.
In addition, it has been reported that aPL cause
endothelial cell activation and blood coagulation
by binding to b2GPI on the surface of endothelial
cells46,47. Martinuzzo et al, demonstrated that sera
from leprosy patients APL positive showed platelet
and endothelial cell activation to the same extend
that patients with APS, however they not show a
procoagulant state as demonstred by normal le vels
of markers of blood coagulation48.
We did not find association between treatment
and positivity for aCL or anti-b2GPI antibodies, and
the increase in those who completed MDT as cured
was not associated with a decrease in aPL positivi -
ty, suggesting that aPL may not be as transient as
in other infections. Arvieux et al, 2002 also repor -
ted persistence of anti-b2GPI antibodies in six le -
pro sy patients followed for over two years. 
There are a few case reports referring aPL and
thrombotic phenomenon in patients with le -
prosy17,18,49. However, this may be just a coincidence
since the pathological significance of these anti-
bodies in leprosy is not very clear.
In conclusion, aCL and b2GPI-dependent in le -
prosy are as frequent as those found in APS pa-
tients, however leprosy patients do not present
clinical manifestations of APS. In leprosy-related
aPL, IgM was the prevalent isotype whereas in APS,
IgG was the main isotype. It is possible that the
presence of aPL in leprosy may be simply another
marker of autoimmunity. In contrast to previous
suggestions, we found no evidence to support the
presence of aPL as a transient phenomenon. It
would be interesting to perform a longitudinal fol-
low-up to evaluate the persistence of these anti-
bodies, and to compare the fine specificity of APS
and leprosy-associated anti-b2GPI antibodies.
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